Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes
✍ Scribed by James A. Williams; Jeremy Luke; Sarah Langtry; Sheryl Anderson; Clague P. Hodgson; Aaron E. Carnes
- Book ID
- 101723046
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 277 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0006-3592
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
DNA vaccines have tremendous potential for rapid deployment in pandemic applications, wherein a new antigen is “plugged” into a validated vector, and rapidly produced in a validated, fermentation—purification process. For this application, it is essential that the vector and fermentation process function with a variety of different antigen genes. However, many antigen genes are unpredictably “toxic” or otherwise low yielding in standard fermentation processes. We report cell bank and fermentation process unit operation innovations that reduce plasmid‐mediated metabolic burden, enabling successful production of previously known toxic influenza hemagglutinin antigen genes. These processes, combined with vector backbone modifications, doubled fermentation productivity compared to existing high copy vectors, such as pVAX1 and gWiz, resulting in high plasmid yields (up to 2,220 mg/L, 5% of total dry cell weight) even with previously identified toxic or poor producing inserts. Biotechnol. Bioeng. 2009;103: 1129–1143. © 2009 Wiley Periodicals, Inc.